Subscribe for the newsletter
Mobile Navigation
Subscribe for the Newsletter
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Directory
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
MYR Pharma
Sort By
Newest First
1 / 1
Sign in
1 / 1
Hepatitis
MYR Pharma Announces Presentation of Interim Results of MYR 203, a Phase 2 Study of Myrcludex in Combination with Pegylated Interferon in Chronic Hepatitis Delta
MYR Pharma
PR-M10-18-NI-107
Oct 31, 2018
